Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose …
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose … TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level. TTI-622 monotherapy shows 6/18 (33%) objective responses at 0.8 to 8 mg/kg dose levels, including 3/6 (50%) objective […]
Read More